1bfb6928-ebaf-4a6c-b70e-f170e2c721f9.jpg
December 18, 2019

Could Preventive Psychiatry Do More Harm Than Good?

As we learn more about the genetic risk factors for psychiatric disorders, some experts are calling for personalized prevention strategies, including drug therapy, based on genetic test results. But there are ethical questions about this approach, including potential harms – in the form of social stigma and fear-- to people without a psychiatric condition who learn that they are at risk of developing one. This topic is one of many covered in the current issue of Braingenethics, a newsletter produced by a collaborative project of The Hastings Center and Columbia University Medical Center. Read the issue. Subscribe for free.

 
 

In the Media: Should Scientists Be Their Own Guinea Pigs?

Many scientists experiment on themselves – half admitted to having done so in a survey conducted earlier this year. But can scientists who are their own guinea pigs – for example, fasting to study its health effects, taking nutritional supplements in anti-aging studies, or taking an experimental drug -- remain unbiased? In an interview with Elemental, Hastings Center research scholar Karen Maschke raises ethical concerns. “We have a scientific enterprise in place that values good data and well-designed studies so that you can be confident that at least the methods were reliable, the findings are valid, and people can reproduce the studies and get similar results. That’s the ethos of the scientific method,” says Maschke, who is also the editor of Ethics & Human Research, a Hastings Center journal. “Someone doing experiments on themselves to some extent undermines that enterprise.” Read the article.

 

Helping Seriously Ill Patients Access "Last Resort" Medicines


The Compassionate Use Advisory Committee, headed by Hastings Center Fellow Arthur Caplan, of NYU Langone, received the Reagan-Udall Foundation for the Food and Drug Administration’s Innovation Award on December 11. The committee was recognized for transforming how expanded access requests, also known as compassionate use requests, are granted by drug developers. “Our goal is to help drug companies better evaluate patient requests for experimental therapies and make these therapies available,” Caplan said. “This is the patient’s last resort in many cases.” He said the program represents a very practical application of bioethical  theories of fairness and justice to directly helping patients and their families—a very real example of “translational bioethics.” Read more.

color-facebook-48.png
color-twitter-48.png
color-link-48.png
Donate

The Hastings Center is funded by people like you. Please support The Hastings Center. Established in 1969, The Hastings Center has been studying the social and ethical issues in health care, science, and technology for 50 years.

Subscribe to the Hastings Center Report here. Subscribe to Ethics & Human Research here.

We strongly value your privacy and would never sell, give, or otherwise share your information. If you no longer wish to receive emails from the Center, you may Unsubscribe or Update Your Preferences. For further information, please visit our website at www.thehastingscenter.org, or email us at [email protected]. Copyright © 2019 The Hastings Center, All rights reserved.

You are receiving this email because of your interest in The Hastings Center.

Our mailing address is:
The Hastings Center
21 Malcolm Gordon Rd.
Garrison, NY 10524

Add us to your address book